ArticleFrontiers in immunology2026
Stratified lymph node yield thresholds after neoadjuvant immunochemotherapy: a surgical benchmark for survival in oral squamous cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The adequacy of neck dissection following neoadjuvant immunotherapy combined with chemotherapy (NICT) for locally advanced oral squamous cell carcinoma (OSCC) lacks evidence-based benchmarks. This study aimed to define and validate extent-specific lymph node dissection (LND) adequacy thresholds associated with survival outcomes. Methods: In a development and validation study, the training cohort comprised 256 consecutive patients with locally advanced OSCC treated with NICT and surgery at Henan Cancer Hospital (2019-2022). An independent cohort of 199 patients from the First Affiliated Hospital of Zhengzhou University (2020-2022) served for validation. Patients were stratified by surgical extent: unilateral (Group Un) or bilateral (Group Bi) neck dissection. Optimal LND thresholds predictive of 3-year overall survival (OS) were determined using restricted cubic splines and maximally selected rank statistics. For Group Un, the threshold (LND-Un) was based on total lymph node yield; for Group Bi, the threshold (LND-Bi) was based on the average yield per side. Survival and safety outcomes were compared between patients meeting ("Adequate") or not meeting ("Inadequate") these thresholds. Results: The optimal thresholds were 20 total lymph nodes for unilateral dissections (LND-Un) and 18 nodes per side on average for bilateral dissections (LND-Bi). In the training cohort, inadequate LND was independently associated with worse OS (Group Un: adjusted hazard ratio [aHR] 2.42, 95% CI 1.47-3.99, p<0.001; Group Bi: aHR 2.29, 95% CI 1.20-4.37, p=0.012) and disease-free survival (DFS). Inadequate LND was also linked to a higher risk of major complications in Group Un (adjusted odds ratio 2.15, 95% CI 1.06-4.38, p=0.034). These findings were robustly validated in the external cohort, where the LND-based model demonstrated good discrimination (C-index for OS: 0.71), excellent calibration, and positive net benefit on decision curve analysis. Conclusion: This study establishes and validates stratified, surgical extent-specific thresholds for lymph node dissection adequacy after NICT in OSCC. Achieving a yield of ≥20 nodes in unilateral dissection or an average of ≥18 nodes per side in bilateral dissection is independently associated with significantly improved survival and an acceptable safety profile. These benchmarks provide a tangible, evidence-based guide for surgical quality assessment and decision-making in the post-NICT setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.